Effects of organic extracts and their different fractions of five Bangladeshi plants on in vitro thrombolysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101088661 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6882 (Electronic) Linking ISSN: 14726882 NLM ISO Abbreviation: BMC Complement Altern Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-2019]
    • Subject Terms:
    • Abstract:
      Background: The increasingly high incidence of ischemic stroke caused by thrombosis of the arterial vessels is one of the major factors that threaten people's health and lives in the world. The present treatments for thrombosis are still unsatisfactory. Herbal preparations have been used since ancient times for the treatment of several diseases. The aim of this study was to investigate whether herbal preparations possess thrombolytic activity or not.
      Methods: An in vitro thrombolytic model was used to check the clot lysis effect of the crude extracts and fractions of five Bangladeshi plant viz., Trema orientalis L., Bacopa monnieri L., Capsicum frutescens L., Brassica oleracea L. and Urena sinuata L. using streptokinase as a positive control and water as a negative control. Briefly, venous blood drawn from twenty healthy volunteers was allowed to form clots which were weighed and treated with the test plant materials to disrupt the clots. Weight of clot after and before treatment provided a percentage of clot lysis.
      Results: Using an in vitro thrombolytic model, different fractions of five Bangladeshi medicinal plants namely T. orientalis, B. monnieri, C. frutescens, B. oleracea and U. sinuata showed various range of clot lysis activity. Chloroform fractions of T. orientalis, B. monnieri, C. frutescens, B. oleracea and U. sinuata showed highest significant (P < 0.05 and P < 0.001) clot lysis activity viz., 46.44 ± 2.44%, 48.39 ± 10.12%, 36.87 ± .27%, 30.24 ± 0.95% and 47.89 ± 6.83% respectively compared with positive control standard streptokinase (80.77 ± 1.12%) and negative control sterile distilled water (5.69 ± 3.09%). Other fractions showed moderate to low clot lysis activity. Order of clot lysis activity was found to be: Streptokinase > Chloroform fractions > Methanol (crude) extract > Hydro-methanol fractions > Ethyl acetate fractions > n-hexane fractions > Water.
      Conclusions: Our study suggests that thrombolytic activity of T. orientalis, B. monnieri and U. sinuata could be considered as very promising and beneficial for the Bangladeshi traditional medicine. Lower effects of other extracts might suggest the lack of bio-active components and/or insufficient quantities in the extract. In vivo clot dissolving property and active component(s) of T. orientalis and B. monnieri for clot lysis could lead the plants for their therapeutic uses. However, further work will establish whether or not, chloroform soluble phytochemicals from these plants could be incorporated as a thrombolytic agent for the improvement of the patients suffering from atherothrombotic diseases.
    • References:
      Ann Intern Med. 1991 Mar 1;114(5):417-23. (PMID: 1899546)
      Circulation. 1995 Feb 15;91(4):1182-8. (PMID: 7850957)
      Chin Med J (Engl). 2000 Aug;113(8):706-11. (PMID: 11776053)
      Am J Med. 2000 Jul;109(1):52-8. (PMID: 10936478)
      Blood Coagul Fibrinolysis. 2011 Apr;22(3):197-205. (PMID: 21311321)
      BMJ. 1995 Dec 2;311(7018):1506. (PMID: 8520368)
      Soc Sci Med. 1992 Apr;34(7):735-46. (PMID: 1376497)
      Thromb J. 2006 Sep 12;4:14. (PMID: 16968529)
      Life Sci. 2005 Apr 15;76(22):2607-19. (PMID: 15769484)
      Acta Haematol. 1990;84(3):139-43. (PMID: 2123064)
      Recent Pat Endocr Metab Immune Drug Discov. 2011 Jan;5(1):33-49. (PMID: 22074576)
      J Nutr. 2001 Oct;131(10):2619-22. (PMID: 11584080)
      N Engl J Med. 2008 Aug 28;359(9):938-49. (PMID: 18753650)
      AJR Am J Roentgenol. 2014 Jul;203(1):54-61. (PMID: 24951195)
      BMC Complement Altern Med. 2013;13:25. (PMID: 23363538)
      BMC Complement Altern Med. 2011;11:52. (PMID: 21718504)
      J Thromb Thrombolysis. 2007 Feb;23(1):9-23. (PMID: 17111203)
      Am J Clin Nutr. 2002 Jul;76(1):93-9. (PMID: 12081821)
      Ann Intern Med. 1990 Apr 1;112(7):529-38. (PMID: 2107781)
      Prog Drug Res. 2008;65:45, 47-118. (PMID: 18084913)
      PLoS One. 2014;9(9):e107290. (PMID: 25198771)
      Biochim Biophys Acta. 2002 Apr 24;1586(3):243-53. (PMID: 11997076)
      Infect Immun. 1998 Oct;66(10):4976-80. (PMID: 9746606)
      Pharmacogn Rev. 2013 Jan;7(13):67-72. (PMID: 23922459)
      Trends Biochem Sci. 2000 Feb;25(2):53-9. (PMID: 10664583)
      J Org Chem. 1973 Apr 6;38(7):1420-1. (PMID: 4694234)
      Am J Clin Nutr. 2000 Oct;72(4):922-8. (PMID: 11010932)
      Int Immunopharmacol. 2011 Mar;11(3):390-8. (PMID: 21056709)
    • Accession Number:
      0 (Fibrinolytic Agents)
      0 (Plant Extracts)
      EC 3.4.- (Streptokinase)
    • Publication Date:
      Date Created: 20150424 Date Completed: 20151214 Latest Revision: 20181202
    • Publication Date:
      20220302
    • Accession Number:
      PMC4414290
    • Accession Number:
      10.1186/s12906-015-0643-2
    • Accession Number:
      25902818